Benzinga | Aug 10, 2020 04:31PM EDT

Cara Therapeutics Q2 EPS $(0.54) Beats $(0.67) Estimate, Sales $5.63M Beat $5.06M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.67) by 19.4 percent. This is a 6.9 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $5.63 million which beat the analyst consensus estimate of $5.06 million by 11.34 percent. This is a 8.18 percent increase over sales of $5.21 million the same period last year.